Hims & Hers Health Faces Investor Lawsuit Over Alleged Misconduct

Got story updates? Submit your updates here. ›

Kahn Swick & Foti, LLC, a prominent securities litigation law firm, has initiated an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) and its officers and directors. This follows a recent securities class action lawsuit against the company, which alleges it failed to disclose material information about its business relationship with Novo Nordisk and made misrepresentations about its operations and prospects.

Why it matters

The investigation and lawsuit raise serious concerns about Hims & Hers' business practices and transparency with investors. As a publicly traded telehealth company, Hims & Hers' alleged misconduct could have significant implications for its future and the trust in the broader digital health industry.

The details

The investigation by Kahn Swick & Foti is focused on whether Hims & Hers' officers and directors breached their fiduciary duties to shareholders or violated state or federal laws. This comes after Novo Nordisk terminated its partnership with Hims & Hers, citing the company's failure to adhere to laws prohibiting mass sales of compounded drugs and its dissemination of deceptive marketing that put patient safety at risk.

• On June 23, 2025, Novo Nordisk announced it was terminating its partnership with Hims & Hers.
• A securities class action lawsuit was subsequently filed against Hims & Hers, alleging the company failed to disclose material information and made misrepresentations about its business.
• Recently, the court presiding over the case denied Hims & Hers' motion to dismiss, allowing the case to move forward.

What’s next

The court presiding over the securities class action lawsuit against Hims & Hers will continue to hear the case, which could lead to further developments and potential consequences for the company.